Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2012Journal of Clinical OncologyOpen Access

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBarbara ProRARanjana H. AdvaniPBPauline Brice

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pro et al. (2012) studied this question.

synapsesocial.com/papers/6a154626d64fa333899f7639https://doi.org/10.1200/jco.2011.38.0402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents2006 · 482 citations
  2. 2Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type2006 · 63 citations
  3. 3Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma2006 · 112 citations
  4. 4Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas1990 · 68 citations
  5. 5The Robust Inference for the Cox Proportional Hazards Model1989 · 2,563 citations